Syros Pharmaceuticals, Inc.·4

Sep 14, 4:05 PM ET

Quirk Gerald E 4

4 · Syros Pharmaceuticals, Inc. · Filed Sep 14, 2023

Insider Transaction Report

Form 4
Period: 2023-09-12
Quirk Gerald E
Chief Legal Officer
Transactions
  • Award

    Restricted Stock Units

    2023-09-12+30,00030,000 total
    Common Stock (30,000 underlying)
Footnotes (2)
  • [F1]Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
  • [F2]These RSUs will vest as to one third (1/3rd) of the shares underlying the award on September 30, 2024 and as to an additional one third (1/3rd) of such shares at the end of each successive year thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION